Bristol-Myers has Opdivo lung cancer setback as sales beat estimates
By Michael Erman NEW YORK (Reuters) - Bristol-Myers Squibb Co said on Thursday it pulled an application seeking U.S.
By Michael Erman
NEW YORK (Reuters) - Bristol-Myers Squibb Co said on Thursday it pulled an application seeking U.S. approval for a combination of its drugs to treat lung cancer, even as it announced better-than-expected fourth-quarter earnings on strong sales of one of those medicines, the immunotherapy Opdivo.
The drugmaker, which announced a planned $74 billion acquisition of biotech Celgene Corp earlier this month, said it withdrew the U.S. application for the combination of Opdivo and its older immunotherapy Yervoy as an initial, or first-line, treatment for advanced lung cancer. Bristol said it needs to collect more data on the benefits of the combination to patients whose cancer cells have a biomarker called tumor mutational burden (TMB) above a certain level.
It made the decision after discussions with the U.S. Food and Drug Administration.
The company's shares were flat at $49.96 midday trading. Analysts suggested that the regulatory setback has been priced into the stock since it released data from a closely-watched lung cancer study in October.
Opdivo, Bristol's most important growth driver, has lost much of its luster as Merck & Co's rival drug Keytruda seized dominance in advanced lung cancer, the most lucrative oncology market.
The withdrawal raises new questions about the company's overall strategy and approach in advanced lung cancer, Credit Suisse analyst Vamil Divan said in a research note. Divan said he did not believe an approval specifically for high-level TMB lung cancer would have had much near-term impact.
Opdivo, which is approved to treat several types of cancer, continues to do well however. Fourth-quarter sales of $1.8 billion easily exceeded the average analyst estimate of $1.47 billion, according to IBES data from Refinitiv.
Last October, the possible approval date for the combination therapy was pushed back by three months to late May, after the company released data showing no difference in survival rates between patients whose tumors had high or low TMB levels.
Bristol said it is still pursuing a lung cancer approval for the combination in patients with a different biomarker called PD-L1 being tested in a separate part of the same study. Opdivo inhibits PD-L1, which cancer cells use to avoid detection from the immune system.
Some analysts and investors have suggested that one reason Bristol may have launched its bid for Celgene was over concerns about Opdivo's ability to compete in the all-important lung cancer market.
Excluding one-time items, Bristol-Myers said it earned 94 cents a share in the quarter, topping analysts' average expectations by 9 cents.
Bristol also forecast 2019 adjusted earnings of $4.10 to $4.20 per share, excluding any impact from the Celgene deal. Analysts, on average, had estimated earnings of $4.17 for the year.
The New York-based company reported net earnings of $1.19 billion, or 73 cents a share, compared with a loss of $2.3 billion, or $1.42 a share, last year, when it took a large charge related to U.S. corporate tax reform.
Revenue of $5.97 billion was in line with analyst estimates.
(Reporting by Michael Erman; Additional reporting by Manas Mishra; Editing by Bill Berkrot)
This story has not been edited by Firstpost staff and is generated by auto-feed.
By Robin Emmott and John Irish | BRUSSELS/PARIS BRUSSELS/PARIS France and Germany will agree to a U.S. plan for NATO to take a bigger role in the fight against Islamic militants at a meeting with President Donald Trump on Thursday, but insist the move is purely symbolic, four senior European diplomats said.The decision to allow the North Atlantic Treaty Organization to join the coalition against Islamic State in Syria and Iraq follows weeks of pressure on the two allies, who are wary of NATO confronting Russia in Syria and of alienating Arab countries who see NATO as pushing a pro-Western agenda."NATO as an institution will join the coalition," said one senior diplomat involved in the discussions. "The question is whether this just a symbolic gesture to the United States
BEIJING Chinese President Xi Jinping on Wednesday called for greater efforts to make the country's navy a world class one, strong in operations on, below and above the surface, as it steps up its ability to project power far from its shores.China's navy has taken an increasingly prominent role in recent months, with a rising star admiral taking command, its first aircraft carrier sailing around self-ruled Taiwan and a new aircraft carrier launched last month.With President Donald Trump promising a US shipbuilding spree and unnerving Beijing with his unpredictable approach on hot button issues including Taiwan and the South and East China Seas, China is pushing to narrow the gap with the U.S. Navy.Inspecting navy headquarters, Xi said the navy should "aim for the top ranks in the world", the Defence Ministry said in a statement about his visit."Building a strong and modern navy is an important mark of a top ranking global military," the ministry paraphrased Xi as saying.